The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society
Section snippets
How can we achieve integration between cardiology and oncology with the best practice of medicine?
1. Collaborate at the outset with ongoing research
A. Define CV risk assessment at the beginning of research protocols
There is burgeoning evidence that CV risk factors may have a substantial impact on the cardiac toxicity of cancer chemotherapeutic agents19 and the preventive treatment of CV-related comorbid conditions can have a significant benefit on all-cause mortality and cardiac-related outcomes.20 Because many easily modifiable CV risk factors are not routinely measured in oncology
Conclusions
Cardioncology is a new, interdisciplinary area that is evolving rapidly, based on a comprehensive approach for the management of cancer patients with cardiac diseases. Because there are a lack of evidence-based indications to guide treatment choices and an urgent need for experts in this setting, cardioncology represents a new, largely unexplored clinical field of topical research. The clinicians and researchers involved in this effort have the ambitious task of investigating these scenarios
Statement of Conflict of Interest
All authors declare that there are no conflicts of interest.
References (23)
- et al.
The year in atherothrombosis
J Am Coll Cardiol
(2007) - et al.
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Lancet
(2007) - et al.
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Ann Oncol
(2008) - et al.
A critical review of clinical arteriogenesis research
J Am Coll Cardiol
(2009) - et al.
Stem cells and repair of the heart
Lancet
(2004) - et al.
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy
JACC
(2010) - et al.
Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring
Am J Cardiol
(2009) A new frontier: cardio-oncology
Cardiologia
(1996)- et al.
Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study
BMJ
(2008) - et al.
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Oncologist
(2010)
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention
J Natl Cancer Inst
Cited by (70)
Chemotherapy-Induced Arrhythmia – Underrecognized and Undertreated
2021, American Journal of MedicineCitation Excerpt :Cardio-oncologists work alongside oncologists to plan oncology care and undertake screening prior to, during, and after treatment for cardiovascular disease. The International Cardio-oncology Society was born in 2009,3 and subsequent to this the field of cardio-oncology has seen rapid expansion, with a 2016 position paper published by the European Society of Cardiology dividing cardio-oncological disease into 9 main categories:4 Myocardial dysfunction and heart failure
Cardio-Oncology rehabilitation- challenges and opportunities to improve cardiovascular outcomes in cancer patients and survivors
2020, Journal of CardiologyCitation Excerpt :In adults, long-term follow-up studies of cancer survivors have highlighted the issue of CVD as a competing risk and the need for pre-treatment CVD risk factor (CVRF) assessment, CVD monitoring during treatment, and survivorship care after treatment [5,6]. Cardio-oncology (onco-cardiology) is a new interdisciplinary field with the common goal of completing cancer treatment and improving the clinical outcomes of high-risk patients or patients receiving high-risk cancer treatment [7–10]. As high-risk treatments, radiotherapy and anthracyclines are known to be associated with cardiotoxicity [11,12].
Cardio-Oncology Education and Training: JACC Council Perspectives
2020, Journal of the American College of CardiologyManagement of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
2020, Annals of OncologyCitation Excerpt :Symptomatic patients with significant reduction in LVEF are classified as stage C HF (structural heart disease with prior or current symptoms of HF) and should be treated with HF-specific medications in accordance with clinical practice guidelines.167,168 In many instances, standard cardiac-based therapy may stabilise or correct abnormalities that would allow anticancer therapy to continue.151 However, these interventions are only likely to be effective when initiated early in the course of HF.157,169
Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States
2017, Clinical Lymphoma, Myeloma and Leukemia
Statement of Conflict of Interest: see page 92.